Get the Stockscreener App
11.74
3.62%
0.41
After Hours:
11.74
Sellas Life Sciences Group Inc stock is traded at $11.74, with a volume of 3.84M.
It is up +3.62% in the last 24 hours and down -17.09% over the past month.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.
See More
Previous Close:
$11.33
Open:
$11.5
24h Volume:
3.84M
Relative Volume:
0.52
Market Cap:
$2.37B
Revenue:
-
Net Income/Loss:
$-29.46M
P/E Ratio:
-51.42
EPS:
-0.2283
Net Cash Flow:
$-28.17M
1W Performance:
+1.12%
1M Performance:
-17.09%
6M Performance:
+184.26%
1Y Performance:
+586.55%
1-Day Range:
$11.38
$12.00
1-Week Range:
$11.20
$12.53
52-Week Range:
$1.39
$15.88
Sellas Life Sciences Group Inc Stock (SLS) Company Profile
Name
Sellas Life Sciences Group Inc
Sector
Industry
Phone
(646) 200-5278
Address
7 TIMES SQUARE, NEW YORK, NY
Compare SLS vs VRTX, MRNA, REGN, ARGX, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SLS
Sellas Life Sciences Group Inc
|
11.74 | 2.34B | 0 | -29.46M | -28.17M | -0.2283 |
VRTX
Vertex Pharmaceuticals Inc
|
504.73 | 133.37B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
190.01 | 79.40B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
735.20 | 81.13B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
919.21 | 60.03B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
206.64 | 43.93B | 742.00K | -1.37B | -1.07B | -7.0731 |
Sellas Life Sciences Group Inc Stock (SLS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jul-21-21 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-01-18 | Initiated | Oppenheimer | Outperform |
| Apr-02-18 | Initiated | H.C. Wainwright | Buy |
| Mar-19-18 | Upgrade | Maxim Group | Hold → Buy |
Sellas Life Sciences Group Inc Stock (SLS) Latest News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of SELLAS Life Sciences Group, Inc.SLS - PR Newswire
SLS Stock Sparks Retail Buzz Ahead of AACR Presentation On Experimental Cancer Therapy - Stocktwits
SLS Stock Snaps 3-Quarter Winning Streak — Why Retail Traders Are Watching Sellas’ Lease And AML Pipeline - Stocktwits
Despite Heavy Hedge Fund Support, Why Sellas Life Sciences (SLS) Fell 16.6% in Q3 - Yahoo Finance
Can SELLAS Life Sciences (SLS) Turn Early CDK9 Pancreatic Data Into a Durable Oncology Edge? - Yahoo Finance
SLS Stock Climbs Premarket: Here’s What Smart Money Is Doing As Sellas Nears Critical Phase 3 AML Readout - Stocktwits
Sellas Life Sciences Updates Executive Benefits Amid Retail Buyout Speculation - Intellectia AI
SELLAS Life Sciences Group, Inc. (SLS) stock price, news, quote and history - Yahoo Finance Australia
SELLAS Life Sciences Group (SLS) Stock May Be Trading At A Premium On Fresh Pancreatic Cancer Data - Yahoo Finance
SELLAS Life Sciences Group (SLS) Could Be Fully Priced After Fresh SLS009 Pancreatic Data - Yahoo Finance
SLS Stock Rises Overnight: Retail Thinks CEO Just Dropped Buyout Clues Ahead Of Fox Appearance - Stocktwits
SLS Stock Tracks Worst Month Since March: Investor Slashes Stake By Over 30% As Quiet Period Begins Ahead Of AML Readout - Stocktwits
Why Did SLS, BB, OUST Stocks Surge To 52-Week Highs Today? - Stocktwits
Sellas Life Sciences Draws Significant Retail Buzz As Traders Eye REGAL Phase 3 Catalyst – SLS Stock Soars 15% - Stocktwits
SLS Stock Edges Higher As Wall Street, Retail Expect Another MRNA Moment - Stocktwits
SLS Stock Jumps Ahead Of CEO’s Fox Appearance: Retail Bets AML Readout Could Spark Big Pharma Bidding War - Stocktwits
SLS Stock In Spotlight After Vanguard Capital Discloses 5.19% Stake – Retail Calls It ‘Huge Vote Of Conviction’ As AML Trial Readout Nears - Stocktwits
SLS Stock Hits Over 5-Year High: Retail Traders Bet Big On Breaking $25 As AML Readout Looms - Stocktwits
SLS CEO Angelos Stergiou Highlights Extended Capital Runway To Pursue Key Milestones, Growth Opportunities – A Look At The Important Numbers - Stocktwits
SLS Stock Logs Record H1 As AML Trial Nears Finish Line — Why Are Retail Traders Refusing To Cash Out? - Stocktwits
SLS Stock Extends Rally Overnight: CEO Says ‘Bullish’ Leukemia Data Could Drive NCCN Recognition For GPS - Stocktwits
SLS Stock Clocks Three Straight Weeks Of Gains On Cancer Vaccine Spillover, REGAL Trial Data Anticipation - Stocktwits
SLS Stock Tests $5 Again: Retail Targets ‘No’ Vote On 20M Share Dilution Push Before AML Trial Results - Stocktwits
SLS Stock Jumps Overnight: ‘Potent’ AML Drug Data Ahead Of Cancer Summit Fuels Fresh Momentum - stocktwits.com
SLS Stock Slips 3% As Pancreatic Cancer Lab Data Leave REGAL Wait Unanswered - Stocktwits
SLS: SELLAS Life Sciences Group Inc Latest Stock Price, Analysis, News and Trading Ideas - Stocktwits
SELLAS Life Sciences: New Pancreatic Cancer Data Arrives While the REGAL Trial Stays the Real Catalyst - TOP1markets
Sellas reports preclinical data on CDK9 inhibitor SLS009 - Investing.com
SELLAS Life Sciences Presents Preclinical Data Demonstrating SLS009 Activity in Pancreatic Cancer Models at the 2026 AACR Conference on Pancreatic Cancer - The Manila Times
Sellas reports preclinical data on CDK9 inhibitor SLS009 By Investing.com - Investing.com Canada
SELLAS Life Sciences Presents Preclinical Data - GlobeNewswire
SLS Stock July Rout Deepens: ‘Pharma Bro’ Martin Shkreli Questions Timing Of AML Trial, Says Data May Wait Until Christmas - Stocktwits
SLS Stock Slides Premarket: Traders Brace For Key Arbitration Ruling In GPS China Payment Dispute - Stocktwits
SLS Stock Turns Green After 3-Day Rout: Five Investors Add Shares As Key AML Trial Nears Final Trigger - Stocktwits
SLS Stock Hits Over 3-Year High As AML Drug Trial Nears Final Readout — Wall Street Sees 30% More Upside - Stocktwits
SLS Stock Rises Overnight: Why Retail Traders Prefer Sellas Over IBRX, ONDS, PYPL As Most Bullish Pick - stocktwits.com
SLS Stock Snaps 2-Day Slide: Sellas’ SLS009 AML Trial Spotlights Big Pharma Drug Combo From ABBV, RHHBY And BMY - Stocktwits
SLS Stock Sees Worst Day In Over A Month — But Prediction Market Flashes 83% Odds For November AML Trial Success - Stocktwits
SLS Stock Slips Overnight Ahead Of Pancreatic Cancer Conference — Retail Looks For Clues To SLS009’s Next Trial - Stocktwits
SLS, IBRX Eye Green Month As Biotech ETF Gains Steam: Analyst Sees ‘Continued Opportunities’ In Immuno-Oncology - Stocktwits
SLS Stock Heads For Worst Month In Over 2 Years — But Retail Bulls ‘Hold’ For AML Readout And Buyout Hopes - Stocktwits
SLS Stock Logs Best Day In Over 2 Weeks: Citigroup Builds Nearly $5M Stake Ahead Of Key AML Trial Trigger - Stocktwits
Sellas CEO Angelos Stergiou Says ‘100% Certain’ AI Can Be Used To Beat Cancer - Stocktwits
Why Did SLS, MRNA, ABCL Stocks Surge To 52-Week Highs Last Week? - Stocktwits
SLS Stock Jumps Premarket: CEO Says GPS AML Data Has ‘Very Good Chance’ To Beat Earlier Survival Outcomes - Stocktwits
Sellas Life Sciences Group Inc Stock (SLS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
0.82%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):